NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for cancer patients using its ProTide technology. Its pipeline includes Acelarin, NUC-3373 and NUC-7738. Acelarin is a nucleotide analog and is a ProTide transformation of gemcitabine for the treatment of cancer. Acelarin is designed to generate and maintain higher concentrations of the anti-cancer metabolite inside the tumor. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). NUC-3373 is being developed for patients with advanced solid tumors. It is developing NUC-3373 as a therapy for colorectal cancer and other solid tumors. NUC-7738 is a ProTide of 3’-deoxyadenosine and is able to enter cells independently of nucleoside transporters. It is developing NUC-7738 for patients with either solid or hematological malignancies.